Photoactivation of Autologous Materials with a New Reliable, Safe and Effective Set-Up
- Apr 30
- 3 min read
Dr. Hernán Pinto Introduction In recent years, regenerative medicine has moved from an ambitious concept to a practical clinical reality. From stem cell therapies to platelet-rich plasma treatments, the idea of using a patient’s own biological materials to promote healing has gained significant traction. But as promising as these therapies are, innovation has slowed—until now. A growing area of interest known as photoactivation (or photomodulation) may offer a way to unlock even greater therapeutic potential.
What Is Photoactivation?
Photoactivation refers to the controlled exposure of biological materials—such as blood-derived plasma or serum—to specific wavelengths of light. This process aims to “condition” these materials, enhancing their biological activity before they are reintroduced into the body.
The underlying principle comes from photobiology: when light is absorbed by cellular photoreceptors, it can trigger biochemical signaling cascades that influence cell proliferation, inflammation, and tissue repair. Experimental studies have reported increased cellular activity under defined light doses, particularly in the red and near-infrared spectrum.
The Challenge: Controlling Light as a Therapeutic Tool
Despite strong preclinical evidence, translating photobiomodulation into reliable clinical protocols has been difficult. The core challenge is physical rather than biological: ensuring that light energy is delivered in a controlled, measurable, and uniform way.
Key barriers include:
Loss of light due to reflection and scattering
Uneven exposure of biological material
Lack of standardized dosing systems
Variability in container geometry and material properties
Without solving these issues, reproducible therapeutic outcomes are difficult to achieve.
A Technical Solution: Optimized Receptacle Design
The study by Hernán Pinto and colleagues addresses this engineering problem by introducing a specifically designed receptacle for photoactivation of autologous materials.
Key features include:
Construction from a medical-grade polymer (Terlux 2812HD)
Thin 1 mm walls to minimize optical loss
Geometry optimized for uniform light distribution
Capacity to hold approximately 10 ml of biological material
The goal is to maximize the interface between light and tissue while maintaining safety and structural consistency. What the Data Shows
Using spectrophotometric analysis across a broad wavelength range (280–1500 nm), the researchers measured how much light passes through the system.
The findings are notable:
Average light transmittance: ~85.8%
Average reflectance: ~8.9%
Overall energy reaching the sample: >90% in key therapeutic ranges
Importantly, efficiency remained stable across the clinically relevant spectrum (approximately 450–1450 nm), which is commonly used in photobiomodulation research.
Why This Is Important
From a clinical engineering perspective, the significance lies in control and reproducibility, as it enables predictable light dosing, reduced variability between treatments, improved standardization of protocols, and enhanced safety margins in energy delivery. In effect, this shifts photoactivation from a loosely defined experimental technique into a quantitatively controlled and potentially scalable clinical procedure.
Clinical Relevance and Evidence Scope
Domain | Key Point | Interpretation |
Clinical engineering significance | Predictable light dosing | Enables controlled and reproducible photon exposure to biological material |
Clinical engineering significance | Reduced variability between treatments | Improves consistency across sessions and devices |
Clinical engineering significance | Standardization of protocols | Supports development of reproducible photomodulation workflows |
Clinical engineering significance | Improved safety margins | Reduces risk of under- or over-exposure in energy delivery |
Overall impact | Shift in methodology | Moves photoactivation from largely empirical practice toward measurable, engineering-controlled procedure |
What is demonstrated | Efficient and controlled light transmission | Validates optical performance of the delivery system |
What is not demonstrated | Clinical efficacy | No evidence provided for therapeutic benefit in patients |
Study scope | Physical validation only | Focuses on optical and mechanical performance, not biological outcomes |
Next requirement | Clinical trials | Needed to determine real-world therapeutic effectiveness |
Future Potential
If future research confirms clinical efficacy, this approach could expand the use of autologous therapies across multiple fields, including:
Orthopedics and sports medicine
Wound healing and tissue repair
Dermatology and aesthetic medicine
Inflammatory and degenerative conditions
Because the system uses a patient’s own biological material, it aligns with broader trends in personalized and minimally invasive medicine.
Conclusion
This work represents a foundational step in making photoactivation a more precise and controllable technology. By addressing the physical limitations of light delivery, it creates the conditions needed for more rigorous clinical investigation.
The next phase will determine whether this technological advance translates into meaningful therapeutic outcomes. For now, it establishes an important principle: in photobiomodulation, engineering precision is as critical as biological insight.
Reference:
Pinto, H. (2020). Photoactivation of autologous materials with a new reliable, safe and effective set-up. Aesthetic Medicine, 6(1), 35–38.
Learn about the new technology of Photoactivation of Autologous Materials in the
upcoming IFAAS Mini-Fellowship:
IFAAS Mini Fellowship (Hands-on)
Anti-Aging Stem Cell Therapy: Japan Edition
15 June, 2026 - Tokyo, Japan - [Register Now] 19 August, 2026 - Seoul, South Korea - [Register Now]
More Upcoming Global Events
Comments